Protocol Ledger

NCT06951646 · Phase II · RECRUITING

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Interventional Phase II clinical trial protocol NCT06951646 sponsored by Second Xiangya Hospital of Central South University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-10 Enrollment: 70 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06951646
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)70 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06951646
Protocol FieldVerified Registry Value
NCT IdentifierNCT06951646
Consolidated Lead SponsorSecond Xiangya Hospital of Central South University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment70 participants (ESTIMATED)
Registered Start Date2026-03-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI